NICE rejects Erbitux again
This article was originally published in Scrip
Health technology assessors for England and Wales are preparing to reject Merck Serono's (Merck KGaA) Erbitux (cetuximab) in yet another indication: recurrent and/or metastatic squamous cell carcinoma of the head and neck.
You may also be interested in...
Local health authorities in Coventry, UK, say it is most unlikely that vaccination with GlaxoSmithKline's Cervarix (human papillomavirus vaccine) was the cause of the death of a 14-year-old schoolgirl on September 28th.
Patents on Janssen-Cilag's (Johnson & Johnson) anti-epileptic Topamax/Epitomax (topiramate) expired in many European countries on September 25th, and generics companies are launching their own versions quickly.
Lilly's Alimta (pemetrexed) has been recommended as a first-line treatment for some patients in England and Wales with non-small cell lung cancer (NSCLC) in binding guidance for the national health service.